My NCBISign In

Display Settings:

Format

Send to:

Choose Destination
    Subst Abus. 2012;33(1):48-59.

    A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.

    Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PD, Nunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ES, O'Brien CP.

    Source

    University of Pennsylvania, Philadelphia, Pennsylvania, USA. coviello d@mail.trc.upenn.edu

    Abstract

    A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.

    PMID:
    22263713
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3365863
    [Available on 2013/1/1]

    Publication Types, MeSH Terms, Substances, Grant Support

    Publication Types

    MeSH Terms

    Substances

    Grant Support

    LinkOut - more resources

    Full Text Sources

    Molecular Biology Databases

      Supplemental Content

      Icon for Atypon

      Save items

      loading

      Related citations in PubMed

      See reviews... See all...

      Recent activity

      Clear Turn Off Turn On

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      You are here: NCBI > Literature > PubMed
      Write to the Help Desk